Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL)

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 32; no. 15_suppl; p. 8079
Main Authors Campelo, Rosario Garcia, Felip, Enriqueta, Massuti, Bartomeu, Majem, Margarita, Carcereny Costa, Enric, Palmero, Ramon, Molina-Vila, Miguel Angel, Martinez, Pablo, Marti-Ciriquian, Juan Luis, Alonso-Jaudenes Curbera, Guillermo, Pallares, Cinta, Cardenal, Felipe, Gonzalez-Arenas, Maria Carmen, Mayo-de las Casas, Clara, Sanchez-Ronco, Maria, Rosell, Rafael
Format Journal Article
LanguageEnglish
Published 20.05.2014
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2014.32.15_suppl.8079